The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Open accessAbstract
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These investigations have established that volumetric decline occurs initially in medial temporal lobe grey matter, following tau protein deposition, and is closely correlated to cognitive decline.”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the regional level, abnormality is evident in medial temporal lobe areas first (hippocampus and entorhinal cortex), then in lateral temporal lobe areas (mid-temporal gyrus and fusiform gyrus) and finally in frontal lobe areas (Jack Jr. et al 2010, Young et al 2014).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because measures of all biomarkers studied to date have considerable overlap with those found other types of dementia (as well the cognitively normal elderly population), it remains difficult to determine whether or not cognitive impairment is due to AD or another more dominant and concurrent process.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is Tau pathology and synapse loss that temporally correlate with cognitive impairment and precede overt neurodegeneration (Jack et al., 2010; Scheff et al., 2006; Spires-Jones and Hyman, 2014”
From Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies (2018) · cites this paper as Jack et al., 2010
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Firstly, cognitive decline is more closely correlated to neurodegeneration than tau accumulation (Jack Jr. et al 2010).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer’s disease (AD) is characterized by deposition of hallmark pathological peptides and neurodegeneration that progress across partially overlapping neuroanatomical and temporal axes1,2.”
From Integrated multimodal cell atlas of Alzheimer’s disease (2024) · cites this paper as [2]
In the citing paper
“Autosomal dominant mutations to the MAPT (tau) gene lead to neuronal tangle pathology and frontotemporal dementia but not to amyloid plaques 122,123 , suggesting that tau pathology does not induce Aβ pathology.”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [123]
In the citing paper
“Amyloid plaques appear a decade or two before clinical symptoms of AD, but it is tau pathology and synapse loss that correlate best with cognitive impairment during disease progression (Jack et al., 2010).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Jack et al., 2010
In the citing paper
“Extensive biomarker and imaging studies indicate that amyloid-β aggregation is the earliest pathological event in Alzheimer’s disease, followed at a later stage by pathological changes of tau aggregation extending beyond the limbic system to the neocortex, which correlates with brain atrophy and cognitive decline2,3.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [2]
In the citing paper
“Their timeline states that in individuals who develop AD, Aβ plaque deposition and reduced CSF Aβ occur first. Next, CSF tau levels rise. These changes manifest years before clinical signs or symptoms develop. Later on hippocampal atrophy appears, followed shortly thereafter by memory decline and eventually dementia. Full progression from Aβ changes to clinical decline takes approximately 10 to 20”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“data argue symptoms generally manifest only after plaques stop forming (Figure 5) [205, 216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“As people meeting preclinical AD criteria may remain cognitively stable for many years [205, 214], these trials will take a long time to complete.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues 18 conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations that can be detected years before psychometrically and clinically noticeable deterioration in cognition, behavior, and function.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [18]
In the citing paper
“The neuropathological changes that are quintessential for AD diagnosis—namely, the development of amyloid plaques and tau tangles—are considered to develop years before onset of the cognitive changes that characterize AD dementia [26].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I. E., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,721
Cited by
Sorted by citations
Items 701–800 of 1,077
Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 109
Self-citationDiagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 108
Self-citationBeckett, L. A., Donohue, M., Wang, C., Aisen, P. S. S., Harvey, D. J., Saito, N. H., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.004 · Cited by 108
Self-citationArterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study
Wang, Z., Das, S. R., Xie, S. X., Arnold, S. E., Detre, J. A., & Wolk, D. A. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.04.014 · Cited by 108
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, O., Shaw, L. M., Watson, M. H., Nairn, A. C., Umaña, K. L., Biarnes, M. C., Canet‐Avilés, R. M., Jack, C. R., Breton, Y., Cortes, L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12353 · Cited by 108
Self-citationCytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice
Babcock, A. A., Ilkjær, L., Clausen, B. H., Villadsen, B., Dissing-Olesen, L., Bendixen, A. T. M., Lyck, L., Lambertsen, K. L., & Finsen, B. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.03.006 · Cited by 107
Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects
Grothe, M. J., Ewers, M., Krause, B. J., Heinsen, H., & Teipel, S. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.011 · Cited by 107
CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease
Tarawneh, R. M., Lee, J., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318248e568 · Cited by 107
Stomrud, E., Björkqvist, M., Janciauskiene, S. M., Minthon, L., & Hansson, O. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt44 · Cited by 107
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Greater cortical thinning in normal older adults predicts later cognitive impairment
Pacheco, J. L., Goh, J. O. S., Kraut, M. A., Ferrucci, L., & Resnick, S. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.031 · Cited by 106
López‐Sanz, D., Bruña, R., Garcés, P., Cámara, C., Serrano, N., Rodríguez‐Rojo, I. C., Delgado‐Losada, M. L., Montenegro, M. V. R., López-Higes, R., Yus, M., et al. (2016) · Scientific Reports · doi:10.1038/srep37685 · Cited by 106
Imaging plus X: multimodal models of neurodegenerative disease
Oxtoby, N. P., & Alexander, D. C. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000460 · Cited by 105
Gordon, B. A., Blazey, T., Su, Y., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Benzinger, T. L. S. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2642 · Cited by 105
Altered whole-brain white matter networks in preclinical Alzheimer's disease
Fischer, F. U., Wolf, D., Scheurich, A., & Fellgiebel, A. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.06.007 · Cited by 105
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease
Dorey, E., Chang, N., Liu, Q. Y., Yang, Z., & Zhang, W. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1422-z · Cited by 105
Gu, Y., Vorburger, R. S., Scarmeas, N., Luchsinger, J. A., Manly, J. J., Schupf, N., Mayeux, R. P., & Brickman, A. M. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.04.022 · Cited by 105
Wirth, M., Schwarz, C., Benson, G. S., Horn, N., Buchert, R., Lange, C., Köbe, T., Hetzer, S., Maglione, M., Michael, E., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0484-1 · Cited by 105
Li, X., Wang, X., Su, L., Hu, X., & Han, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028188 · Cited by 105
Oh, H., Habeck, C. G., Madison, C. M., & Jagust, W. J. (2012) · Human Brain Mapping · doi:10.1002/hbm.22173 · Cited by 105
Self-citationVitali, P., Migliaccio, R., Agosta, F., Rosen, H., & Geschwind, M. D. (2008) · Seminars in Neurology · doi:10.1055/s-0028-1083695 · Cited by 105
Driscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104
A Blood Gene Expression Marker of Early Alzheimer's Disease
Lunnon, K., Sattlecker, M., Furney, S. J., Coppola, G., Simmons, A., Proitsi, P., Lupton, M. K., Lourdusamy, A., Johnston, C., Soininen, H. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121363 · Cited by 104
Rates of Decline in Alzheimer Disease Decrease with Age
Holland, D., Desikan, R. S., Dale, A. M., McEvoy, L. K., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042325 · Cited by 104
β-Amyloid affects frontal and posterior brain networks in normal aging
Oh, H., Mormino, E. C., Madison, C. M., Hayenga, A. O., Smiljic, A., & Jagust, W. J. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.027 · Cited by 104
Self-citationPark, M., & Moon, W. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.6.827 · Cited by 104
Alzheimer’s disease diagnosis from diffusion tensor images using convolutional neural networks
Marzban, E. N., Eldeib, A. M., Yassine, I. A., Kadah, Y. M., & Initiative, A. D. N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230409 · Cited by 104
Kamondi, A., Grigg-Damberger, M. M., Löscher, W., Tanila, H., & Horvath, A. A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00932-4 · Cited by 104
Increased functional connectivity within medial temporal lobe in mild cognitive impairment
Das, S. R., Pluta, J. B., Mancuso, L., Kliot, D., Orozco, S., Dickerson, B. C., Yushkevich, P. A., & Wolk, D. A. (2012) · Hippocampus · doi:10.1002/hipo.22051 · Cited by 104
Advances in neuroimaging in frontotemporal dementia
Gordón, E., Rohrer, J. D., & Fox, N. C. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13656 · Cited by 104
Longitudinal brain structural changes in preclinical Alzheimer's disease
Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D. A., Carmona‐Iragui, M., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.010 · Cited by 106
Gatys, L. A., Ecker, A. S., & Bethge, M. (2015) · Max Planck Digital Library · doi:10.12751/nncn.bc2015.0220 · Cited by 104
Selnes, P., Aarsland, D., Bjørnerud, A., Gjerstad, L., Wallin, A., Hessen, E., Reinvang, I., Grambaitė, R., Auning, E., Kjærvik, V. K., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121603 · Cited by 103
Viscoelasticity of subcortical gray matter structures
Johnson, C. L., Schwarb, H. D., McGarry, M., Anderson, A. T., Huesmann, G., Sutton, B. P., & Cohen, N. J. (2016) · Human Brain Mapping · doi:10.1002/hbm.23314 · Cited by 103
Amyloid duration is associated with preclinical cognitive decline and tau PET
Koscik, R. L., Betthauser, T. J., Jonaitis, E. M., Allison, S. L., Clark, L. R., Hermann, B. P., Cody, K. A., Engle, J. W., Barnhart, T. E., Stone, C. K., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12007 · Cited by 103
Junkkila, J., Oja, S., Laine, M., & Karrasch, M. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000342116 · Cited by 103
Relationship of dementia screening tests with biomarkers of Alzheimer's disease
Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A., & Morris, J. C. (2010) · Brain · doi:10.1093/brain/awq204 · Cited by 103
Leoni, V. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.088 · Cited by 102
Longitudinal Patterns of β-Amyloid Deposition in Nondemented Older Adults
Sojkova, J., Zhou, Y., An, Y., Kraut, M. A., Ferrucci, L., Wong, D. F., & Resnick, S. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.77 · Cited by 102
Circulating microRNAs as Biomarkers of Alzheimer’s Disease: A Systematic Review
Wu, H. Z. Y., Ong, K. L., Seeher, K. M., Armstrong, N. J., Thalamuthu, A., Brodaty, H., Sachdev, P. S., & Mather, K. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150619 · Cited by 104
Clinical Use and Utility of Amyloid Imaging
Barthel, H., & Sabri, O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185017 · Cited by 102
Sequence of clinical and neurodegeneration events in Parkinson’s disease progression
Oxtoby, N. P., Leyland, L., Aksman, L., Thomas, G. E. C., Bunting, E. L., Wijeratne, P. A., Young, A. L., Zarkali, A., Tan, M. M. X., Bremner, F., et al. (2021) · Brain · doi:10.1093/brain/awaa461 · Cited by 102
Brain Age Estimation From MRI Using Cascade Networks With Ranking Loss
Cheng, J., Liu, Z., Guan, H., Wu, Z., Zhu, H., Jiang, J., Wen, W., Tao, D., & Liu, T. (2021) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2021.3085948 · Cited by 102
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis
Mathotaarachchi, S. S., Wang, S., Shin, M., Pascoal, T. A., Benedet, A. L., Kang, M. S., Beaudry, T., Fonov, V., Gauthier, S. G., Labbe, A., et al. (2016) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2016.00020 · Cited by 102
Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease
García‐Blanco, A., Baquero, M., Vento, M., Gil, E., Bataller, L., & Cháfer‐Pericás, C. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.01.020 · Cited by 102
Estrogen Regulation of Mitochondrial Bioenergetics
Yao, J., & Brinton, R. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00010-6 · Cited by 103
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101
Self-citationBarthel, H., Luthardt, J., Becker, G., Patt, M., Hammerstein, E., Hartwig, K., Eggers, B., Sattler, B., Schildan, A., Hesse, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1821-1 · Cited by 101
Villemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Cc, R., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 101
Gerischer, L. M., Fehlner, A., Köbe, T., Prehn, K., Antonenko, D., Grittner, U., Braun, J., Sack, I., & Flöel, A. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.12.023 · Cited by 101
Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers
Kim, K., Lee, C. H., & Park, C. B. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00107d · Cited by 101
Roles of ApoE4 on the Pathogenesis in Alzheimer’s Disease and the Potential Therapeutic Approaches
Sun, Y.-Y., Wang, Z., & Huang, H. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01365-1 · Cited by 102
A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease
Cardoso, F., Goetz, C. G., Mestre, T., Sampaio, C., Adler, C. H., Berg, D., Bloem, B. R., Burn, D. J., Fitts, M. S., Gasser, T., et al. (2023) · Movement Disorders · doi:10.1002/mds.29683 · Cited by 101
Poon, W. W., Carlos, A. J., Aguilar, B. L., Berchtold, N. C., Kawano, C. K., Zograbyan, V., Yaopruke, T., Shelanski, M. L., & Cotman, C. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463711 · Cited by 101
Podhorná, J., Krahnke, T., Shear, M. A., Harrison, J., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0170-5 · Cited by 101
Insausti, R., & Amaral, D. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374236-0.10024-0 · Cited by 101
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
How early can we predict Alzheimer's disease using computational anatomy?
Adaszewski, S., Dukart, J., Kherif, F., Frackowiak, R. S. J., & Draganski, B. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.015 · Cited by 100
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 100
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
Ong, K. T., Villemagne, V. L., Bahar‐Fuchs, A., Lamb, F., Langdon, N., Catafau, A. M., Stephens, A. W., Seibyl, J. P., Dinkelborg, L. M., Reininger, C. B., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308094 · Cited by 100
Benedict, C., & Grillo, C. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00215 · Cited by 101
Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias
Disbrow, E. A., Stokes, K. Y., Ledbetter, C. R., Patterson, J. C., Kelley, R. E., Pardue, S., Reekes, T. H., Larmeu, L., Batra, V., Yuan, S. S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12305 · Cited by 100
Gallego-Rudolf, J., Wiesman, A. I., Binette, A. P., Villeneuve, S., & Baillet, S. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01763-8 · Cited by 109
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 100
Self-citationHeinzel, S., Metzger, F. G., Ehlis, A., Korell, R., Alboji, A., Haeussinger, F. B., Hagen, K., Maetzler, W., Eschweiler, G. W., Berg, D., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.021 · Cited by 100
Zahodne, L. B., Manly, J. J., Narkhede, A., Griffith, E. Y., DeCarli, C. S., Schupf, N., Mayeux, R. P., & Brickman, A. M. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150530203214 · Cited by 100
Kim, S. H., Kandiah, N., Hsu, J., Suthisisang, C. C., Udommongkol, C., & Dash, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14030 · Cited by 100
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
Tarawneh, R. M., Head, D. M., Allison, S. L., Buckles, V., Fagan, A. M., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0202 · Cited by 99
Cunnane, S. C., Chouinard‐Watkins, R., Castellano, C., & Barberger‐Gateau, P. (2012) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.04.006 · Cited by 99
The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease
Boon, B. D. C., Bulk, M., Jonker, A. J., Morrema, T. H. J., van den Berg, E., Popovic, M. M., Walter, J., Kumar, S., van der Lee, S. J., Holstege, H. H., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02198-8 · Cited by 99
Ahmad, F., Singh, K. P., Das, D., Gowaikar, R., Shaw, E., Ramachandran, A., Rupanagudi, K. V., Kommaddi, R. P., Bennett, D. A., & Ravindranath, V. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6860 · Cited by 99
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
Association of Alzheimer's disease GWAS loci with MRI markers of brain aging
Chauhan, G., Adams, H. H. H., Bis, J. C., Weinstein, G., Yu, L., Töglhofer, A. M., Smith, A. V., van der Lee, S. J., Gottesman, R. F., Thomson, R. J., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.028 · Cited by 98
Self-citationAlzheimer's disease: The amyloid hypothesis on trial
Harrison, J. R., & Owen, M. J. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.167569 · Cited by 98
Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
Mullins, R. J., Reiter, D. A., & Kapogiannis, D. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.530 · Cited by 98
Mechanical property alterations across the cerebral cortex due to Alzheimer’s disease
Hiscox, L. V., Johnson, C. L., McGarry, M., Marshall, H., Ritchie, C. W., van Beek, E. J. R., Roberts, N., & Starr, J. M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz049 · Cited by 98
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Hippocampal Sclerosis in the Elderly
Pao, W. C., Dickson, D. W., Crook, J. E., Finch, N. A., Rademakers, R., & Graff‐Radford, N. R. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31820f8f50 · Cited by 98
Schroeter, M. L., Laird, A. R., Chwiesko, C., Deuschl, C., Schneider, E., Bzdok, D., Eickhoff, S. B., & Neumann, J. (2014) · Cortex · doi:10.1016/j.cortex.2014.02.022 · Cited by 97
Menke, R., Proudfoot, M. J., Wuu, J., Andersen, P. M., Talbot, K., Benatar, M. G., & Turner, M. R. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311945 · Cited by 98
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Seshadri, S., Beiser, A., Au, R., Wolf, P. A., Evans, D. A., Wilson, R. S., Petersen, R. C., Knopman, D. S., Rocca, W. A., Kawas, C. H., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.002 · Cited by 97
Self-citationChabrier, M. A., Cheng, D., Castello, N. A., Green, K. N., & LaFerla, F. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.007 · Cited by 97
Yue, L., Wang, T., Wang, J., Li, G., Wang, J., Li, X., Li, W., Hu, M., & Xiao, S. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00226 · Cited by 97
Local Sleep and Alzheimer’s Disease Pathophysiology
Mander, B. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.525970 · Cited by 97
Structural Plasticity of the Hippocampus in Neurodegenerative Diseases
Weerasinghe-Mudiyanselage, P. D. E., Ang, M. J., Kang, S., Kim, J., & Moon, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063349 · Cited by 97
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Self-citationmTOR signaling and Alzheimer's disease: What we know and where we are?
Davoody, S., Asgari Taei, A., Khodabakhsh, P., & Dargahi, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14463 · Cited by 96
Weise, C. M., Chen, K., Chen, Y., Kuang, X., Savage, C. R., & Reiman, E. M. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.07.016 · Cited by 96
Hippocampal and Amygdala Gray Matter Loss in Elderly Controls with Subtle Cognitive Decline
Zanchi, D., Giannakopoulos, P., Borgwardt, S., Rodriguez, C. K., & Haller, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00050 · Cited by 98
Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease
Rudajev, V., & Novotny, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937056 · Cited by 94
Hill, D., Schwarz, A. J., Isaac, M., Pani, L., Vamvakas, S., Hemmings, R., Carrillo, M. C., Yu, P., Sun, J., Beckett, L. A., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.07.003 · Cited by 96
Self-citationBrain aerobic glycolysis functions and Alzheimer’s disease
Vlassenko, A. G., & Raichle, M. E. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0094-7 · Cited by 96
Topology-Based Kernels With Application to Inference Problems in Alzheimer's Disease
Pachauri, D., Chris Hinrichs, A., Chung, M. K., Johnson, S. C., & Singh, V. (2011) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2011.2147327 · Cited by 96
Initiative, T. A. D. N., Zu, C., Jie, B., Liu, M., Chen, S., Shen, D., & Zhang, D. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9480-7 · Cited by 95
Brandt, J., Buchholz, A. S., Henry-Barron, B. J., Vizthum, D., Avramopoulos, D., & Cervenka, M. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180995 · Cited by 95
Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review
Wiels, W., Baeken, C., & Engelborghs, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00034 · Cited by 95
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q.
- Affiliations
- Mayo Clinic (US)
- University of California, Berkeley (US)
- University of Pennsylvania (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Corresponding author
- Jack, Clifford R
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 9
- Issue
- 1
- Pages
- 119-128
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2819840
- OpenAlex
- W2167840686
- Cited by
- 4,806
- References
- 119
- Citations by year
- 2026: 273 · 2025: 317 · 2024: 278 · 2023: 259 · 2022: 308 · 2021: 321 · 2020: 359 · 2019: 303 · 2018: 267 · 2017: 283 · 2016: 265 · 2015: 273 · 2014: 335 · 2013: 337 · 2012: 301
- FWCI
- 127.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (AG11378)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, amyloid PET, tau protein, brain atrophy, FDG-PET, synaptic dysfunction, neurodegeneration, disease stage, biomarkers, cognitive decline
- MeSH terms
- Aging, Alzheimer Disease, Brain, Cognition Disorders, Humans, Magnetic Resonance Imaging, Models, Neurological, Time Factors, Signal Transduction, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Positron-Emission Tomography, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
